Scinopharm Taiwan, Ltd. · TWSE:1789
Scinopharm Taiwan — 2016 JP Morgan Healthcare Conference
25 slides from Scinopharm Taiwan's conference presentation, Jan 14, 2016
Slide 1: ScinoPharm Management Presentation
TWSE 1789 ScinoPharm Management Presentation 2016 JP Morgan Healthcare Conference Yung Fa Chen, Ph.D. President & CEO Patricia Chou CFO & VP Corporate Development 1
Slide 2: Disclaimer
Disclaimer This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”). Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein.
Slide 3: Table of Content
Confidential Table of Content Overview of ScinoPharm ScinoPharm’s Strategies and Opportunities Operating Results & Outlook 3 3
Slide 4: Overview of ScinoPharm
Overview of ScinoPharm 4
Slide 5: Background
Background Established in 1997 in Taiwan and listed on TWSE in 2011, current market cap around US$1.2 billion Major shareholders include Uni-President Group, National Development Fund, & Taiwan Sugar Facility & organization built in Taiwan by experienced Syntex team, received multiple regulatory ins
Slide 6: World Class API Facilities
World Class API Facilities Taiwan China 6.6 hectares of land, 330K sqft facilities with 6.6 hectares of land with > 250M3 reactor volume >200M3 reactor volume 3 of 7 production lines equipped with high potency 8 of 18 production lines equipped with high potency capabilities for cytotoxics capabiliti
Slide 7: Business Overview
Confidential Business Overview Risk & return balanced model to offer APIs and sterile filling capability for both generic and new drugs 80+ generic APIs developed with 27 APIs launched; 55 US DMFs filed (733 DMFs WW), 29 US DMFs in oncology APIs 100+ NCE CRAM projects, with 5 launched and 6 in phase
Slide 8: 2015 Sales Distribution
Confidential By Indication 2015 Sales Distribution CNS Others 17% 7% By Business CMO BD Oncology CRO 8% 2% By Region 76% 5% Rest of ROW Oncology Asia AU&NZ 63% Generics <1% 12% 5% 85% Generic 77% India US&CAN 18% 42% EU 23% 8 8
Slide 9: Strong Generics Product Portfolio
Strong Generics Product Portfolio Confidential 45 42 40 28 35 30 25 20 unlaunched 3 15 9 14 launched 10 7 3 4 5 5 6 3 3 2 2 2 2 2 6 2 2 3 1 1 1 2 1 3 2 2 2 0 2 9 9 11
Slide 10: Diversified CRAM Portfolio
Confidential Diversified CRAM Portfolio Stage First Launch Year Indication Location Commercial 2005 Eluting Stent US Commercial 2009/2013 Skin Infection/HAP US/EU Commercial 2011 Depression US Commercial 2012 Obesity US Commercial 2013 Seizure US Stage Est. NDA Filing Year Indication Location Phase
Slide 11: ScinoPharm's Strategies and Opportunities
ScinoPharm’s Strategies and Opportunities 11
Slide 12: Long Term Strategies
Confidential Long Term Strategies Transforming to a full-scope pharma company per our core competency of R&D and cGMP manufacturing in high-technical barrier APIs Vertical Integration to Generic Formulations: Developing dossiers per our difficult-to-make APIs to increase value proposition in the sup
Slide 13: Keys to Generic Formulation Business
Keys to Generic Formulation Business Expanding formulation portfolio Building on-site oncology injectable facility and establishing a complete supply chain Sustaining B2B model, promoting our formulations via strategic alliance, especially in China and US/EU Acquiring critical resources via M&A 13
Slide 14: Strategic Alliance Highlights
Strategic Alliance Highlights Partner Product Indications Region Launch Year(E) Remarks Genovate Entecavir Hepatitis B Viral Taiwan 2013* 1st co-developed formulation product launch Oncology 1st US ANDA filing, triggered US FDA inspection in Sagent Myeloid Leukemia US 2016 Injectable Changshu site F
Slide 15: ScinoPharm - Oncology API Leader
Confidential ScinoPharm - Oncology API Leader Stand-Alone API Company ScinoPharm 29 26 Shilpa 12 9 2 Polymed 10 1 3 # Oncology DMF Overlap with SPT MacChem Products 7 5 2 # Non-overlapping Oncology DMF Laurus Labs 7 6 10 # Other DMFs Sichuan Xieli 6 8 13 Chemwerth 3 5 30 Apicore 5 5 22 0 10 20 30 40
Slide 16: ScinoPharm Pipeline Echoes Therapy Trend
Confidential ScinoPharm Pipeline Echoes Therapy Trend Ophthalmology 3% Others 3% Supportive Genetic disorder 3% Chemotherapy 9% care Respiratory 3% 5% Gastrointestinal 6% Hormonal therapy Infectious 9% disease Oncology 6% 34% Targeted Metabolic therapy disorder 10% 77% CV CNS 10% 12% Immunology 10%
Slide 17: Forces Reshaping Chinese Pharma Market
Confidential Forces Reshaping Chinese Pharma Market Policy reform expediting drug approvals, allowing new drug developers to own drug licenses without manufacturing sites Significantly lifting the cost structure & entry barrier in Chinese drug market, with a heavy focus on quality and innovation Mot
Slide 18: Advantages in Growing Chinese Market
Advantages in Growing Chinese Market Direct benefit from the new GMP standards and policy reform Tailor-made product portfolio for Chinese market Domestic presence plus world-class strengths in: * High-technical-barrier oncology APIs * Global first tier customer base * Quality and EHS/GMP compliance
Slide 19: Portfolio for Chinese Aging Society
Portfolio for Chinese Aging Society 14 drug licenses applied and 6 collaborated with local marketers for popular age-related diseases in China Benazepril as the first granted import drug license Oncology Cardiovascular Urology Glaucoma Alzheimer Others *Anastrozole *Benazepril *Tamsulosin **Bimatopr
Slide 20: Operating Results & Outlook
Operating Results & Outlook 20
Slide 21: Historical Performance
Historical Performance Unit: In NT$ million * For Q1-Q3 only 5,088 5,000 4,572 4,098 3,791 3,887 3,953 3,955 4,000 3,145 3,000 2,494 2,000 1,463 1,000 613 1,273 484 872 1,041 1,040 1,170 143 961 484 *440 0 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 21 21
Slide 22: Recent Financial
Recent Financial * In NT$ million Year 2013 2014 Q1-Q3 or 9/30 2015 Total assets* 11,484M 11,372M 11,995M Shareholders’ equity* 9,643M 9,380M 9,701M Sales* 5,088M 4,098M 2,925M Net profit after tax* 1,273M 484M 440M Earnings per share (NT$) 1.88 0.69 0.60 Cash dividends (NT$/share) 1.2 0.2 - Stock d
Slide 23: 2016 API Product Launches
2016 API Product Launches Product Name Region Indications Brand Marketer Regional Sales* WW Sales* Myelodysplastic Azacitidine USA Celgene US$257.2M US$771.9M syndromes (MDS) Desmopressin USA Polyuria Ferring US$140.1M US$393.3M Acetate USA, Hepatitis B US$286M Entecavir Singapore, Bristol-Myers US$
Slide 24: Pipeline Outlook
Pipeline Outlook 4-6 new launches 5-6 new launches 5-6 new launches 1st co-developed US 1st home-made drug US 3 drug products launched in China ANDA launched ANDA filing 1st home-made drug launched in US 2016 2017 2018 2019 2020 3-5 new launches 6-8 new launches 1st self-developed US SPC China FDA i
Slide 25: Brand Quality with Asian Advantages
Confidential Brand Quality with Asian Advantages www.scinopharm.com 25 25
ScinoPharm Taiwan — 2016 JP Morgan Healthcare Conference on 6ix